Abstract
Evolution of frontline treatment for patients with chronic lymphocytic leukemia (CLL) has been driven by the objective of increasing complete remission (CR) rates and achieving maximum elimination of leukemia. As a result, effective combination regimens incorporating new agents such as monoclonal antibodies have been developed. Beyond morphologic CR, evaluation for residual disease by multicolor flow cytometry or molecular techniques may provide a tool to assess potentially more effective therapies. Although new prognostic factors correlate with time to treatment and survival have been identified, the utility of these factors in predicting response rates or response duration has not been established. Clearly, strides have been made in developing effective treatments that are improving remission duration with the ultimate goal of improving survival for patients with CLL. Herein, we review the recent progress in frontline therapies for patients with CLL.
Citations
Oct 20, 2006·Cancer Immunology, Immunotherapy : CII·Amal MansourElizabeth Raveche
Jun 30, 2009·Journal of Immunotherapy·James N KochenderferSteven A Rosenberg
Apr 19, 2011·Blood·William G WierdaUNKNOWN 407 Study Investigators
Mar 16, 2013·OncoTargets and Therapy·Osmond J D'Cruz, Fatih M Uckun
Feb 27, 2008·International Reviews of Immunology·Fatih M Uckun
Jun 17, 2009·Expert Opinion on Pharmacotherapy·David Masiello, Anil Tulpule
Jan 1, 2008·Expert Opinion on Medical Diagnostics·Tom Butler, John G Gribben
Dec 20, 2008·Leukemia Research·Sandra M CampsVincent Lévy
Aug 19, 2007·Experimental Hematology·Laurence LagneauxDominique Bron
Oct 26, 2006·British Journal of Haematology·Fatih M UckunSanjive Qazi
May 3, 2007·Clinical Journal of Oncology Nursing·Kimberly Noonan
Dec 8, 2007·Clinical Journal of Oncology Nursing·Mollie MoranEmma Buckby
Dec 18, 2014·Bioorganic & Medicinal Chemistry·Xinge ZhaoHua Xiang
Jan 21, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Kaci Wilhelm, Daisy Yang
Jul 23, 2014·Oncotarget·Juan M CaraballoJavier León